Results 231 to 240 of about 149,686 (307)

A framework to assess the risk of yellow fever emergence. [PDF]

open access: yesJ Travel Med
Perlant C   +8 more
europepmc   +1 more source

Systemic and Local Adiposity in the Bone Marrow Microenvironment Associated With Improved Prognosis in Hodgkin Lymphoma: Imaging and Molecular Analysis

open access: yesInternational Journal of Cancer, Volume 159, Issue 3, Page 782-796, 1 August 2026.
Schematic overview of systemic and bone marrow‐specific adiposity in Hodgkin Lymphoma (HL). Body Mass Index was associated with bone marrow (BM) involvement, relapse, and mortality (1). In contrast, increased yellow marrow density was associated with poorer prognosis (2).
Andreia Matos   +22 more
wiley   +1 more source

The Yellow Fever Fly

open access: yesPsyche: A Journal of Entomology, 1880
Hermann August Hagen
doaj   +1 more source

Spindle Cell Fibromatosis of the Breast: A Lesson in Malignancy Mimicry

open access: yesClinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT Spindle cell fibromatosis of the breast (SCFB) is a rare benign tumor that closely mimics malignancy on imaging and clinical examination. Accurate diagnosis relies on histopathology and immunohistochemistry, particularly β‐catenin staining, to guide appropriate management and avoid overtreatment while addressing its locally aggressive behavior
Valerie Fiore   +5 more
wiley   +1 more source

Pickpocket315 affects male mating behavior in the yellow fever mosquito Aedes aegypti. [PDF]

open access: yesG3 (Bethesda)
Wyer CAS   +7 more
europepmc   +1 more source

The Airplane and Yellow Fever [PDF]

open access: yesAmerican Journal of Public Health and the Nations Health, 1938
openaire   +2 more sources

Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 274-285, July 2026.
BRAF inhibitors and MEK inhibitors (MEKi) have reshaped the treatment of BRAFV600‐mutant malignancies; however, cutaneous adverse drug reactions (ADRs) remain a frequent and clinically impactful toxicity. Although clinical trials provide insight into their safety profiles, real‐world data on dermatologic ADRs are limited.
Natalia Sauer   +3 more
wiley   +1 more source

Beyond dengue and Oropouche: The urgent need for yellow fever preparedness in Cuba. [PDF]

open access: yesNew Microbes New Infect
Cañete R   +2 more
europepmc   +1 more source

Indianapolis Consensus Recommendations for Promoting Diversity and Equity in Cancer Clinical Trials: “The Indianapolis Black Paper”

open access: yesDiversity &Inclusion Research, Volume 3, Issue 3, July 2026.
ABSTRACT Cancer mortality is inequitably distributed across the U.S. and globally, with historically marginalized groups, particularly racial and ethnic minorities, being disproportionately affected. Disproportionate representation in clinical cancer research is a consequence of inequitable access as well as a central factor contributing to outcome ...
Maya N. Birhiray   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy